Xcout Intel
Arch Biopartners Inc. competitors & alternatives
The 12 closest competitors and alternatives to Arch Biopartners Inc. among biotech companies — ranked by similarity to what Arch Biopartners Inc. actually does, not by market-cap band.
Subscribe to see Arch Biopartners Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Arch Biopartners Inc.
Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
Arch Biopartners Inc. at a glance
Arch Biopartners Inc. is a biotech company headquartered in Saint Louis, Canada. It is publicly listed (ARCH) with a market capitalisation of $41.1M. Xcout tracks 25 named people at Arch Biopartners Inc., including Paul A Lang (Chief Executive Officer & Director).
Arch Biopartners Inc. leadership
- Paul A LangChief Executive Officer & Director
- John T. DrexlerPresident, Chief Operating Officer & Director
- Keith WilliamsGroup President of Western Operations & President of Thunder Basin Coal Company
- George J. Schuller Jr.Senior Vice President & Chief Operating Officer
- Matthew C. GiljumSenior Vice President & Chief Financial Officer
- Andrew BishopChief Financial Officer, Director
19 more named people on record for Arch Biopartners Inc., with roles, board committees and tenure — see the full roster →
Arch Biopartners Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | Undisclosed | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Arch Biopartners Inc. competitors
Ranked by semantic similarity — how close each company is to Arch Biopartners Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Asep Medical Holdings Inc., operating primarily through its subsidiary ASEP Medical Inc., is dedicated to advancing both a rapid diagnostic system for Sepsis and a range of peptide-based therapeutic treatments applicable across various medical conditions. The company, initially incorporated in 2020 under the name Trenchant Life Sciences Investment Corp., later rebranded to its present title, Asep Medical Holdings Inc. Its corporate base of operations is located in Vancouver, Canada.
Similar biotech company
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Similar biotech company
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Biotechnology
Mesentech Inc. is an active for-profit biotechnology company focused on drug pipelines, therapeutic areas, and proprietary technology platforms. Headquartered in Vancouver, British Columbia, Canada, the company operates with a small team specializing in clinical research and development.
Life Sciences
ArrePath is a biotechnology research company based in Princeton, New Jersey, focusing on AI-enabled oral small-molecule discovery. The company uses proprietary artificial intelligence and machine learning workflows proven in antibacterial discovery.
Similar biotech company
Omnix Medical is a biopharmaceutical company that develops novel antibiotic agents and antimicrobial peptides to treat infections caused by drug-resistant bacteria. The company focuses on creating first-in-its-class anti-infective therapeutics, such as its lead compound OMN6, to target life-threatening bacterial strains.
Biotechnology
Liminal BioSciences is a biopharmaceutical company headquartered in Laval, Quebec, Canada, focused on developing innovative small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases.
Biotechnology
Attune Biotech Inc. is a biopharmaceutical company that develops novel medicines to treat underserved disorders, focusing on neuroimmune, inflammatory, infectious disease, and metabolic applications. The company utilizes a proprietary platform approach featuring its flagship candidate, Lodonal, which is engineered with pharmaceutical-grade consistency and precision dosing to restore immune balance.
Similar biotech company
Microbix Biosystems Inc. is a life science enterprise dedicated to advancing human health globally, including markets across North America and Europe. Established in 1988 and headquartered in Mississauga, Canada, the company specializes in developing and marketing unique biological and technological products. A significant part of its business involves producing essential biological reagents for the diagnostic industry. This encompasses antigens vital for immunoassays, alongside its distinctive Quality Assessment and Proficiency (QAP) products. These QAPs are instrumental for clinical laboratories, providing support for proficiency testing, the development and validation of diagnostic assays, and optimizing routine lab operations. Furthermore, Microbix applies its deep biological knowledge and infrastructure to create additional proprietary offerings. Among these are DxTM, a viral transport medium crucial for stabilizing patient specimens prior to laboratory analysis, and Kinlytic Urokinase, a biopharmaceutical thrombolytic drug employed to treat blood clots. The company channels its QAP sales to accreditation organizations, diagnostic companies, and clinical laboratories via an extensive network of regional distributors.
Biotechnology
Soricimed Biopharma Inc. is a biopharmaceutical company with operations located in Moncton, New Brunswick and Boston, Massachusetts. The company focuses on research and therapeutic development.
Similar biotech company
Appili Therapeutics Inc., a Canadian biopharmaceutical firm headquartered in Halifax and founded in 2015, specializes in sourcing and advancing innovative treatments to address critical gaps in infectious disease medicine. The company's diverse pipeline includes Favipiravir, utilized for pandemic influenza and COVID-19, and the clinical-stage antifungal ATI-2307, which targets cryptococcal meningitis and invasive candidiasis. Other programs feature ATI-1503, a new class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral metronidazole suspension; ATI-1801, a novel topical formulation of paromomycin for treating cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine designed for Francisella tularensis. Additionally, Appili maintains a strategic collaboration with AiPharma Global Holdings LLC for the ongoing development of Avigan/Reeqonus (favipiravir).
Similar biotech company
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Arch Biopartners Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Arch Biopartners Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →